Serum level of soluble interleukin-2 receptor alpha correlates with the clinical course and activity of Wilms' tumour and soft tissue sarcomas in children.
Wilms' tumour (WT) and soft tissue sarcomas (SA) in children lack reliable biochemical markers. This study was carried out to determine the clinical significance of serum soluble interleukin-2 receptor alpha (sIL-2Ralpha) in the diagnostics and treatment monitoring of children with WT and SA. The study included 48 children: ten with WT, eight with SA and 30 healthy controls. The sIL-2Ralpha levels (ELISA) and rates of elevated sIL-2Ralpha values were estimated prospectively at diagnosis and in complete remission during treatment and after therapy. As the dependence on age was determined, the levels of sIL-2Ralpha were expressed as multiplications of the upper value of the normal range for a particular age ( xN). Median pretreatment levels of sIL-2Ralpha in patients exceeded those of healthy controls (1.79 xN for WT and 1.53 for SA vs. 0.61 for controls; p < 0.001) as did the rates of elevated sIL-2Ralpha values (80% of WTand 87.5% of SA patients vs. 0% of controls). Good response to therapy was paralleled by a significant decline of pretreatment sIL-2Ralpha levels and its elevated rates. Thus, sIL-2Ralpha determination may be of some value in the diagnostics and treatment monitoring of childhood WT and SA.
Bien
E
E
Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdansk, Poland. ebien@amg.gda.pl
Balcerska
A
A
Kuchta
G
G
D000367:Age Factors; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D002648:Child; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood*; D012074:Remission Induction; D012509:Sarcoma / Q000175:diagnosis*; D016896:Treatment Outcome; D009396:Wilms Tumor / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D053645:Interleukin-2 Receptor alpha Subunit